The 13 most recent market catalysts affecting $ATAI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 55
Cantor Fitzgerald Suspends Neutral Rating on AtaiBeckley Inc
Cantor Fitzgerald has suspended its 'Neutral' rating on AtaiBeckley Inc. This action typically occurs when an analyst is re-evaluating their coverage, awaiting new information, or …
Sep 3, 2026
Corporate Catalyst
Neutral
Impact 55
Jim Cramer Isn't Sure If There’s Upside In This Health Care Stock
This 8-K filing details Jim Cramer's 'Mad Money Lightning Round' commentary on several stocks, providing his short-term outlooks. Cramer expressed skepticism about AtaiBeckley (ATA…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 85
AtaiBeckley Says Hart-Scott-Rodino Waiting Period For Merger With Eli Lilly Expired On Aug 28, 2026; UK Competition Authority Has No Further Questions On Merger As Of August 21, 2026
AtaiBeckley announced significant progress in its merger with Eli Lilly. The expiration of the Hart-Scott-Rodino waiting period in the US and the UK CMA's indication of no further …
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 65
Deutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8
Deutsche Bank analyst David Hoang downgraded Atai Life Sciences (ATAI) from a 'Buy' to a 'Hold' rating and significantly lowered the price target from $12 to $8. This action reflec…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 65
HC Wainwright & Co. Downgrades AtaiBeckley to Neutral, Lowers Price Target to $7.5
HC Wainwright & Co. downgraded AtaiBeckley (ATAI) from a 'Buy' rating to 'Neutral' and drastically cut its price target from $25 to $7.5. This significant revision by a covering an…
Jul 17, 2026
Corporate Catalyst
Bearish
Impact 65
Jefferies Downgrades AtaiBeckley to Hold, Lowers Price Target to $7.5
Jefferies analyst Andrew Tsai downgraded AtaiBeckley (ATAI) from a 'Buy' to a 'Hold' rating and lowered the price target from $10 to $7.5. This action reflects a reduced confidence…
Jul 16, 2026
Corporate Catalyst
Bearish
Impact 65
Canaccord Genuity Downgrades AtaiBeckley to Hold, Announces $8 Price Target
Canaccord Genuity analyst Sumant Kulkarni downgraded AtaiBeckley (ATAI) from a 'Buy' to a 'Hold' rating and set a new price target of $8. This action signals a more cautious outloo…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 85
Shares of psychedelic-related biotech companies are trading higher amid sympathy with AtaiBeckley after the company announced it will be acquired by Lilly in a deal worth up to $3.8 billion.
The acquisition of AtaiBeckley by Lilly is a major corporate catalyst for the psychedelic-related biotech sector. It provides significant validation for the therapeutic potential a…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 95
AtaiBeckley shares are trading higher after the company announced it will be acquired by Lilly.
This headline represents a major corporate catalyst, driving a significant positive movement in AtaiBeckley's stock due to the acquisition premium. For Lilly, the impact is likely …
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 95
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks (CORRECTED)
The filing reports that AtaiBeckley (ATAI) shares skyrocketed after-hours due to news of potential acquisition talks with Eli Lilly (LLY). This is a major corporate catalyst for AT…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.